MK-6420. Lantheus is also attempting to expand its radiopharmaceutical diagnostic offerings, the most notable of which is MK-6420, a second-generation F18-labeled PET imaging agent that targets ...

Through the transaction, Lantheus has acquired OCTEVY, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate ...

"We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront. This strategic collaboration creates a clear path to commercialization with an ideal partner in the ...

The acquisition was first announced on January 28, 2025. Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, ...